上海睿昂基因科技股份有限公司 国泰海通作为承接公司首次公开发行股票并在科创板上市持续督导工作的保荐机构，原委派李勤女士和 张晓博女士担任持续督导期间的保荐代表人，持续督导期间至2024年12月31日，但截止2024年12月31 日，公司首次公开发行并在科创板上市发行募集资金尚未使用完毕，募集资金余额为1,795.35万元，国 泰海通将继续履行对公司剩余募集资金管理及使用情况的持续督导责任。因工作变动，张晓博女士不再 担任公司首次公开发行股票并在科创板上市持续督导期间的保荐代表人，为保证持续督导工作有序进 行，国泰海通委派孙兴涛先生（简历见附件）接替张晓博女士担任持续督导期间的保荐代表人，继续履 行持续督导责任。 本次保荐代表人变更不影响国泰海通对公司的持续督导工作。本次变更后，公司首次公开发行股票并在 科创板上市的持续督导保荐代表人为李勤女士和孙兴涛先生。 证券代码：688217 证券简称： 睿昂基因 公告编号：2025-031 关于变更持续督导保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 上海睿昂基因 ...

上海睿昂基因科技股份有限公司 关于变更持续督导保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海睿昂基因科技股份有限公司（以下简称"公司"或"睿昂基因"）于 近日收到公司保荐机构国泰海通证券股份有限公司（以下简称"国泰海通"） 出具的《国泰海通证券股份有限公司关于变更持续督导保荐代表人的通知函》。 国泰海通作为承接公司首次公开发行股票并在科创板上市持续督导工作的 保荐机构，原委派李勤女士和张晓博女士担任持续督导期间的保荐代表人，持 续督导期间至 2024 年 12 月 31 日，但截止 2024 年 12 月 31 日，公司首次公开 发行并在科创板上市发行募集资金尚未使用完毕，募集资金余额为 1,795.35 万 元，国泰海通将继续履行对公司剩余募集资金管理及使用情况的持续督导责任。 因工作变动，张晓博女士不再担任公司首次公开发行股票并在科创板上市持续 督导期间的保荐代表人，为保证持续督导工作有序进行，国泰海通委派孙兴涛 先生（简历见附件）接替张晓博女士担任持续督导期间的保荐代表人，继续履 行持续督导责 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Ruian Gene, indicating a recent stock price increase and a significant change in net profit [1][2] - As of the first quarter of 2025, Ruian Gene reported a revenue of 54.738 million yuan, reflecting a year-on-year decrease of 14.72%, while net profit surged by 529.26% to 3.355 million yuan [2] - The company has a market capitalization of 1.276 billion yuan and a price-to-book ratio of 1.40, which is the lowest in 31 days [1][2] Group 2 - Ruian Gene specializes in the research, production, and sales of in vitro diagnostic products, with key products including leukemia-related fusion gene testing kits and various gene mutation testing kits [1] - The company holds 114 medical device products approved or registered with the National Medical Products Administration, including 31 Class III medical devices [1] - The average price-to-earnings ratio (PE) in the industry is significantly higher than that of Ruian Gene, indicating potential undervaluation [2]

1 国泰海通证券股份有限公司关于 上海睿昂基因科技股份有限公司首次公开发行股票 并在科创板上市之保荐总结报告书 | 保荐机构名称： | 国泰海通证券股份有限公司 | | --- | --- | | 保荐机构编号： | Z29131000 | 经中国证券监督管理委员会《关于同意上海睿昂基因科技股份有限公司首次公 开发行股票注册的批复》（证监许可[2021]1126 号）批复，上海睿昂基因科技股份 有限公司（以下简称"上市公司"、"公司"、"睿昂基因"或"发行人"）首次 公开发行股票 1,390.00 万股，每股面值人民币 1 元，每股发行价格人民币 18.42 元， 募集资金总额为人民币 25,603.80 万元，扣除发行费用后，实际募集资金净额为人民 币 19,479.70 万元。本次发行证券已于 2021 年 5 月 17 日在上海证券交易所科创板上 市。原海通证券股份有限公司担任其持续督导保荐机构，持续督导期间为 2021 年 5 月 17 日至 2024 年 12 月 31 日。 2022 年 12 月，根据上市公司向不特定对象发行可转换公司债券的需要，其聘 请原国泰君安证券股份有限公司担任本次向不特定 ...

Core Viewpoint - Ruiang Gene's stock closed at 20.89 yuan, up 2.50%, with a market-to-book ratio of 1.28 and a total market value of 1.167 billion yuan [1] Company Overview - Ruiang Gene specializes in the research, production, sales, and scientific services of in vitro diagnostic products, with key products including leukemia-related fusion gene testing kits and various gene mutation testing kits [1] - As of December 31, 2024, the company holds 114 medical device products approved or registered by the National Medical Products Administration, including 31 Class III medical device registration products [1] Financial Performance - In the first quarter of 2025, the company reported operating revenue of 54.738 million yuan, a year-on-year decrease of 14.72%, while net profit reached 3.355 million yuan, a significant increase of 529.26%, with a sales gross margin of 71.00% [2] - The company's price-to-earnings (P/E) ratio (TTM) is -90.15, and the price-to-book (P/B) ratio is 1.28, with a total market value of 1.167 billion yuan [2]

上海睿昂基因科技股份有限公司 舆情管理制度 (2025 年 4 月) 第一章 总则 第一条 为提高上海睿昂基因科技股份有限公司（以下简称"公司"）应对 各类舆情的能力，建立快速反应和应急处置机制，及时、妥善处置各类舆情对公 司股价、公司商业信誉及正常生产经营活动造成的影响，维护公司市场形象与保 护投资者合法权益，根据《公司法》《上海证券交易所科创板股票上市规则》《上 海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等相关法律、 行政法规、规章、规范性文件，结合《公司章程》和公司实际情况，特制定本制 度。 第二条 本制度所称舆情包括： （一）新闻报道、报刊文章、电视节目、社交媒体、网络论坛等渠道对公司 进行的负面评价或歪曲事实的报道； （二）社会上已存在，尚未得到证实但已经或将给公司造成不良影响的传言、 谣言、虚假信息等； （三）可能或者已经影响社会公众投资者投资取向，造成公司股价异常波动 的信息； （四）其他涉及公司信息披露且可能对公司股票及其衍生品交易价格产生 较大影响的事件信息。 第四条 舆情管理的基本原则 （一）舆情监测与预警：根据舆情的性质、传播范围、影响力等因素，设定 预警指标，开展日 ...

Financial Performance - The company's revenue for Q1 2025 was ¥54,738,007.28, a decrease of 14.72% compared to ¥64,188,221.36 in the same period last year[3] - Net profit attributable to shareholders increased significantly by 529.26% to ¥3,355,013.27 from ¥533,165.07 year-on-year[3] - Basic earnings per share rose to ¥0.06, reflecting a 500% increase from ¥0.01 in the previous year[4] - Total operating costs for Q1 2025 were CNY 55,633,595.22, down from CNY 64,568,301.80 in Q1 2024, reflecting a reduction of 13.8%[22] - Net profit for Q1 2025 was CNY 1,841,429.31, compared to a net loss of CNY 1,437,353.69 in Q1 2024, indicating a significant turnaround[23] - The company reported an operating profit of CNY 1,797,016.26, compared to an operating loss of CNY 2,213,823.14 in the previous year[22] Research and Development - Research and development (R&D) expenses totaled ¥10,988,068.94, down 32.99% from ¥16,398,202.66, with R&D expenses accounting for 20.07% of revenue, a decrease of 5.48 percentage points[4] - Research and development expenses for Q1 2025 were CNY 10,988,068.94, down from CNY 16,398,202.66 in Q1 2024, a decrease of 32.5%[22] Cash Flow and Assets - The net cash flow from operating activities was ¥10,538,321.54, a decline of 8.51% from ¥11,518,866.49 in the previous year[3] - As of March 31, 2025, the company's cash and cash equivalents amounted to ¥111,923,118.97, a decrease from ¥139,151,947.97 on December 31, 2024, representing a decline of approximately 20%[17] - The total current assets as of March 31, 2025, were ¥471,364,891.50, slightly up from ¥470,136,956.05 at the end of 2024[17] - The company's total financial assets increased to ¥112,006,062.48 as of March 31, 2025, from ¥93,526,046.51 at the end of 2024, marking a growth of approximately 19.67%[17] - The cash and cash equivalents at the end of Q1 2025 stood at $108,586,964.85, down from $145,047,025.93 at the end of Q1 2024, a decrease of 25.1%[27] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 3,990[11] - The largest shareholder, Xiong Hui, holds 10,176,397 shares, representing 18.22% of the total shares[11] - The company completed a share buyback of 669,621 shares, representing 1.20% of the total share capital, with a total expenditure of ¥17,021,747.99[15] Legal and Management Changes - The company announced a change in its management structure due to legal issues involving key personnel, with a new acting representative appointed[14] - The company is under investigation for illegal activities involving its key executives, which may impact future operations and governance[14] Liabilities and Equity - Total liabilities decreased to CNY 54,619,456.99 from CNY 65,057,131.21, a reduction of approximately 16.5%[19] - The company's equity increased to CNY 922,485,901.89 from CNY 920,644,472.58, showing a slight growth[19] Inventory and Accounts Receivable - The company reported accounts receivable of ¥167,694,943.18 as of March 31, 2025, compared to ¥165,928,041.07 at the end of 2024, indicating a slight increase[17] - Inventory as of March 31, 2025, was ¥45,158,971.12, up from ¥43,400,196.20 at the end of 2024, reflecting a growth of approximately 4.05%[17] Exchange Rate Impact - The company experienced a negative impact of $751,726.51 from exchange rate fluctuations on cash and cash equivalents in Q1 2025[27]

金十数据4月24日讯，睿昂基因发布一季报，营业收入为5473.80万元，同比下降14.72%；归属于上市公 司股东的净利润为335.50万元，同比增长529.26%。净利润增长主要系子公司长春技特收到流式细胞相 关研究项目政府补助尾款180万；收回前期单项计提的一笔应收坏账247.63万元。 睿昂基因：一季度净利润同比增长529.26% ...

Core Viewpoint - In a challenging environment for the in vitro diagnostics industry, Ruian Gene (688217.SH) has demonstrated resilience and forward-looking strategies in its annual performance report for 2024, achieving a revenue of 242 million yuan and a significant focus on R&D investment [2][6]. Financial Performance - The company reported a total revenue of 242 million yuan, with its key product, the lymphoma rearrangement reagent kit, generating 36.66 million yuan, reflecting a year-on-year increase of 12.55% [2]. - R&D expenditure reached 62.47 million yuan, accounting for 25.78% of total revenue, indicating a strong commitment to innovation [2]. - Despite a net profit loss of 15.76 million yuan, the company reported a net cash flow from operating activities of 59.98 million yuan, a year-on-year growth of 33% [2]. Business Focus and Product Development - Ruian Gene specializes in the development, production, and sales of in vitro diagnostic products, focusing on blood diseases, solid tumors, and infectious diseases [3]. - The company achieved revenues of 205 million yuan from self-produced reagents, 20.65 million yuan from testing services, and 4.61 million yuan from research services [3]. - Significant breakthroughs were made in high-end molecular diagnostic products, including the BCR-ABL P210 fusion gene testing kit, which received regulatory approval and filled a gap in leukemia monitoring [3]. - A collaboration with Ruijin Hospital led to the development of a molecular typing kit for diffuse large B-cell lymphoma, improving patient outcomes significantly [3]. Technological Advancements - The company has made notable progress in digitalization and AI applications, particularly in hematological oncology, leveraging extensive bioinformatics data to develop prognostic models for various blood cancers [4]. - Ruian Gene has established an automated laboratory capable of processing 20,000 tests daily, enhancing efficiency and clinical response times [5]. Intellectual Property and Innovation - As of the end of 2024, the company holds 58 patents, including 50 invention patents, and has applied for 8 new patents during the reporting period [5]. - The focus on high-quality monitoring data supports future research and intellectual property strategies [5]. Market Outlook and Strategic Initiatives - The in vitro diagnostics market is projected to reach 22.8 billion yuan by 2026, with a compound annual growth rate of 30.6% from 2026 to 2030, indicating a rapidly growing sector [6]. - The company plans to enhance its marketing system and attract high-end talent to maintain its competitive edge in niche markets [6]. - A share buyback plan has been initiated to support employee stock ownership and incentivize staff, with 669,621 shares repurchased, representing 1.20% of total shares [7]. Future Plans - Looking ahead to 2025, the company aims to focus on R&D, market expansion, and governance upgrades, with a commitment to advancing molecular diagnostic technologies and AI innovations [8].

Core Viewpoint - Ruiang Gene (688217.SH) reported a decline in revenue and net profit for the year 2024, indicating financial challenges while maintaining positive cash flow from operating activities [1][2]. Financial Performance - The company achieved operating revenue of 242.31 million yuan in 2024, a decrease of 6.16% compared to 258.21 million yuan in 2023 [2]. - The net profit attributable to shareholders was -15.76 million yuan, a significant decline from a profit of 7.93 million yuan in the previous year, representing a decrease of 298.78% [2]. - The net profit after deducting non-recurring gains and losses was -19.25 million yuan, down from 3.70 million yuan in 2023, marking a decrease of 620.88% [2]. - The net cash flow from operating activities was 59.98 million yuan, reflecting a year-on-year increase of 33.00% from 45.10 million yuan in 2023 [1][2]. Profit Distribution - The company plans not to distribute cash dividends, issue bonus shares, or increase capital reserves for the year 2024, retaining the undistributed profit of 13.83 million yuan for future use [2]. Stock Issuance - Ruiang Gene proposed to authorize the board to issue shares to specific investors, with a financing total not exceeding 300 million yuan, which is capped at 20% of the net assets as of the end of the previous year [4].